ClinicalTrials.gg

Program

brimonidine

Also written as “Brimonidine”, “Brimonidine Tartrate” and “CD07805/47 Gel”.

Its studies are mostly in Glaucoma · Rosacea · Glaucoma, Open-Angle · Conjunctivitis, Allergic · Hyperemia, led by 10 companies.

Furthest: phase 4, since Apr 6, 200752 company-led studies, 2 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie220 open or runningphase 4since Apr 6, 2007Sep 12, 2005none ahead
Galderma Group100 open or runningphase 4since Sep 23, 2014Jun 12, 2008none ahead
Bausch Health Companies70 open or runningphase 3since Oct 8, 2013Oct 8, 2013none ahead
Eye Therapies30 open or runningphase 2since Jan 10, 2011Jan 10, 2011none ahead
Ocugen30 open or runningphase 3since Jul 9, 2018Oct 10, 2017none ahead
Alcon20 open or runningphase 4since Dec 1, 2008May 28, 2003none ahead
Tarian Pharma22 open or runningphase 2since Jan 23, 2025Jan 23, 2025none ahead
Biogen10 open or runningphase 4since Oct 1, 2015Oct 1, 2015none ahead
Innovative Medical10 open or runningphase 4since Jun 30, 2006Jun 30, 2006none ahead
Teva Pharmaceutical Industries10 open or runningphase 3since Oct 31, 2014Oct 31, 2014none ahead

Also a collaborator on its studies: ORA and eurotrials-brasil-consultores-cientificos-ltda.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 37 studies since May 28, 2003.

  1. Mar 12, 2014Phase 2 study in Geographic AtrophyAbbVie · NCT02087085 · 310 enrolled · United States, Australia, France and more
  2. Sep 23, 2014Phase 4 study in RosaceaGalderma Group · NCT02249065 · 205 enrolled · United States
  3. Oct 31, 2014Teva Pharmaceutical Industries's first study: phase 3 study in RosaceaNew to Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries · NCT02289352 · 462 enrolled · United States
  4. Oct 1, 2015Biogen's first study: phase 4 study in Multiple Sclerosis, Relapsing-RemittingNew to BiogenBiogen · NCT02568111
  5. Nov 24, 2015Phase 4 study in RosaceaGalderma Group · NCT02616250 · 190 enrolled · United States, Canada
  6. Jul 19, 2016Phase 4 study in Chronic Persistent Vascular Facial ErythemaGalderma Group · NCT02856919 · 101 enrolled · Brazil
  7. Oct 10, 2017Ocugen's first study: phase 2 study in Dry Eye SyndromesNew to OcugenOcugen · NCT03418727 · 84 enrolled · United States
  8. Jul 9, 2018Phase 3 study in Graft vs Host DiseaseOcugen · NCT03591874 · 59 enrolled · United States
  9. Dec 20, 2018Phase 3 study in Dry Eye SyndromesOcugen · NCT03785340 · 252 enrolled · United States
  10. Apr 29, 2022Phase 3 study in Ocular RednessBausch Health Companies · NCT05360784 · 380 enrolled · United States
  11. Oct 6, 20222 phase 3 studiesBausch Health Companies · NCT05591755, NCT05579730
  12. Mar 21, 2023Phase 3 study in Conjunctivitis, AllergicBausch Health Companies · NCT05815758 · 512 enrolled · United States
  13. Jan 23, 2025Tarian Pharma's first study: phase 2 study in EGFR Inhibitor-associated RashNew to Tarian PharmaTarian Pharma · NCT06818058 · 60 planned · France
  14. Jul 3, 2025Phase 2 study in Chemotherapy Induced Peripheral NeuropathyTarian Pharma · NCT07082764 · 30 planned · France

TargetBeta

“Adrenergic receptor alpha-2 agonist”ChEMBL 37, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
DexmedetomidinerulePfizerphase 446
OxymetazolineruleAbbViephase 420
Phentolamineruleopus-genetics-incphase 418
Epinephrinerulenasus-pharmaphase 417
tizanidineruleTeva Pharmaceutical Industriesphase 411
Clonidinerulepharmafinaphase 45
lofexidineruleuswm-llc-dba-us-worldmedsphase 315

Studies

All 52 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07082764Chemotherapy Induced Peripheral Neuropathy · France2Not yet recruitingTarian PharmaSep 30, 202630
NCT06818058EGFR Inhibitor-associated Rash · France2RecruitingTarian PharmaSep 1, 202660
NCT05815758Conjunctivitis, Allergic · United States3CompletedBausch Health CompaniesSep 18, 2023512
NCT05591755Seasonal Allergic Conjunctivitis · United States3CompletedBausch Health CompaniesAug 9, 2023229
NCT05579730Conjunctivitis, Allergic · United States3CompletedBausch Health CompaniesJul 22, 2023188
NCT05360784Ocular Redness · United States3CompletedBausch Health CompaniesNov 23, 2022380
NCT03785340Dry Eye Syndromes · United States3CompletedOcugenFeb 25, 2019252
NCT03591874Graft vs Host Disease · United States3TerminatedOcugenApr 30, 202059
NCT03418727Dry Eye Syndromes · United States2CompletedOcugenMar 29, 201884
NCT02856919Chronic Persistent Vascular Facial Erythema · Brazil4CompletedGalderma GroupFeb 8, 2017101
NCT02616250Rosacea · United States, Canada4CompletedGalderma GroupSep 2016190
NCT02568111Multiple Sclerosis, Relapsing-Remitting4WithdrawnBiogenAug 20160
NCT02289352Rosacea · United States3CompletedTeva Pharmaceutical IndustriesDec 2014462
NCT02249065Rosacea · United States4CompletedGalderma GroupAug 2015205
NCT02087085Geographic Atrophy · United States, Australia, France and more2TerminatedAbbVieMar 30, 2018310
NCT02039765Hyperemia · United States1CompletedBausch Health CompaniesMar 201412
NCT02003534Glaucoma, Open-Angle · China4CompletedAbbVieFeb 2013376
NCT01959243Hyperemia · United States3CompletedBausch Health CompaniesApr 23, 2014507
NCT01959230Hyperemia · United States3CompletedBausch Health CompaniesDec 20, 201360
NCT01882712Erythema3WithdrawnGalderma GroupSep 20150
NCT01863953Glaucoma · United States2CompletedAbbVieDec 2013112
NCT01687426Glaucoma · United States1CompletedEye TherapiesDec 201215
NCT01675609Ocular Redness · United States2CompletedEye TherapiesOct 201257
NCT01525173Glaucoma · United States4CompletedAbbVieOct 2012137
NCT01355471Rosacea · United States, Canada3CompletedGalderma GroupNov 2011293
NCT01355458Rosacea · United States, Canada3CompletedGalderma GroupSep 2011260
NCT01318733Rosacea · United States3CompletedGalderma GroupJun 2012449
NCT01275105Conjunctivitis, Allergic · United States2CompletedEye TherapiesMar 201168
NCT01241240Glaucoma, Open-Angle · Colombia, Mexico3CompletedAbbVieSep 2013192
NCT01229462Glaucoma · China–CompletedAbbVieSep 2011238
NCT01229410Vitrectomy · United States, Czech Republic1CompletedAbbVieMay 201124
NCT01217606Glaucoma, Open-Angle · Brazil3CompletedAbbVieSep 2014185
NCT01216943Glaucoma · India3CompletedAbbVieAug 2012126
NCT01174030Rosacea · United States2CompletedGalderma GroupDec 2010269
NCT01151904Glaucoma, Angle-Closure · Thailand4TerminatedAbbVieFeb 201217
NCT00989014Rosacea · United States2CompletedGalderma GroupNov 2009122
NCT00972374Rhegmatogenous Macula-off Retinal Detachment · United States, India, Israel and more2CompletedAbbVieOct 201044
NCT00822055Glaucoma, Open-Angle · Canada4CompletedAbbVieNov 2006140
NCT00800540Glaucoma · United States4CompletedAlconJan 201235
NCT00697541Erythematous Rosacea · United States2CompletedGalderma GroupJun 200820
NCT00693485Glaucoma, Open-Angle · United States, Israel2CompletedAbbVieJan 201170
NCT00658619Macular Degeneration · United States, Australia, Germany and more2CompletedAbbVieJun 1, 2010119
NCT00652483Glaucoma · United States3CompletedAbbVieDec 2003433
NCT00651612Glaucoma · United States3CompletedAbbVieJan 2007604
NCT00661479Retinitis Pigmentosa · United States, France, Germany and more2CompletedAbbVieDec 200921
NCT00457795Glaucoma, Open-Angle · United States4CompletedAbbVieFeb 200915
NCT00348400Glaucoma · United States4CompletedInnovative Medical
NCT00332436Ocular Hypertension · United States3CompletedAbbVieNov 2001586
NCT00332384Ocular Hypertension · United States3CompletedAbbVieNov 2001573
NCT00332345Ocular Hypertension · United States2CompletedAbbVieAug 199973
NCT00168363Glaucoma3CompletedAbbVieAug 2006207
NCT00061529Glaucoma, Open-Angle · United States3CompletedAlconJul 2004

How it is read

Names in the registry

  • “Brimonidine”, 4 entries
  • “Brimonidine Tartrate”, 4 entries
  • “CD07805/47 Gel”, 4 entries
  • “CD07805/47”, 3 entries
  • “400 µg Brimonidine Tartrate Implant”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
brimonidine (AbbVie): development program | ClinicalTrials.gg